Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IFLO is Breaking Out -- Ignore unavailable to you. Want to Upgrade?

To: James Strauss who wrote (930)	4/6/2000 5:50:00 PM
From: Sergio H	Read Replies (2) \| Respond to of 1018

Although IFLO is not specifically mentioned, IFLO's sector received favorable comments from BEAR STEARNS: <Industry Overview Medical Supplies & Devices Industry We believe there should be a flight to quality and highlight Johnson & Johnson (JNJ, Attractive) and C.R. Bard Inc. (BCR, Buy). We have checked in with BCR over the last few days. We think BCR should meet or beat our $267 million sales estimate when they report on 4/19. We think the BCR story is high single-digit revenue growth (ex-currency) and mid-teens EPS growth because of operating leverage and new products and product mix. BCR has not had a new product for some time, but BCR has been working for a while on an endoscopic suturing system for Gastric Reflux Disease (GRD).This actually repairs the condition rather than just treating the condition. Based on our research, we think this system could be useful in 15% of the GRD patients, or 750,00 people, translating into a market of about $500 million. We are not changing our numbers on BCR. This product bolsters our confidence in BCR? s ability to bring new products through the development process. BCR trades at 13.5x our 2001 number. We continue to think this is a good time for people to accumulate JNJ. JNJ is trading just above its historic relative lows and is cheap relative to the Street. People are concerned about the issues we have seen of late on the drug side of the business. We believe JNJ will deliver their numbers, JNJ is comfortable they will deliver the numbers. Throughout the year, positive events should occur that will excite investors, such as an important stent approval this summer. If we wait for the outcome of some of the issues that are plaguing JNJ now, it will be too late to buy the stock at a cheap price. (JNJ) Bear Stearns: 12/2000E $3.36 12/2000E $3.85 (JNJ) Consensus: 12/2000E $3.35 12/2001E $3.79 Consensus Rating: 2.1 (last updated 4/5) Healthcare Services/Facilities Sector Update Given the volatility in both the broad market and NASDAQ, we highlight the more traditionally defensive hospital sector and some of the companies we think are trading at attractive valuations. In terms of history, the hospital group for much of the 1990s was viewed as one of the leading ?defensive? sectors in the economy. The basic rationale behind this assumption, of course, was that medical spending trends are typically not correlated with the business cycle, at least at the hospital setting, and wage trends move inversely with the economy. In times of either declining corporate profits (at the aggregate levels) or overall market uncertainty, hospital stocks have historically been strong outperformers. Though cuts enacted under the Balanced Budget Act of 1997, as well as the rise of managed care, eroded the perception of the group's defensiveness, we would argue that Medicare givebacks (current and anticipated) and backlash against managed care cuts is heralding a return to the sector's traditional defensive nature. With all of our companies done with Q4 earnings and Tenet Healthcare reporting solid fiscal Q3 earnings, it appears the earnings environment has improved and has indeed stabilized. Investors should focus on three names in the group in this current environment, namely Columbia/HCA (COL, Buy), Tenet Healthcare (THC, Attractive) and Universal Health Services (UHS, Buy).>